Drugs for Haemophilus Influenzae (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 150)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Temocillin |
Approved, Investigational |
Phase 4 |
|
66148-78-5 |
|
Synonyms:
|
2 |
|
Prednisolone phosphate |
Approved, Vet_approved |
Phase 4 |
|
302-25-0 |
|
Synonyms:
Prednisolone 21-(dihydrogen phosphate)
Prednisolone 21-monophosphate
|
Prednisolone 21-phosphate
|
|
3 |
|
Methylprednisolone |
Approved, Vet_approved |
Phase 4 |
|
83-43-2 |
6741 |
Synonyms:
(6a,11b)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione
(6S,8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-6,10,13-trimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one
(6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
.DELTA.1-6.alpha.-Methylhydrocortisone
11beta,17,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
11-beta,17,21-Trihydroxy-6-alpha-methylpregna-1,4-diene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methyl-1,4-pregnadiene-3,20-dione
11beta,17alpha,21-Trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione
121673-01-6
1-dehydro-6alpha-Methylhydrocortisone
1-Dehydro-6alpha-methylhydrocortisone
1-dehydro-6a-Methylhydrocortisone
1-dehydro-6α-methylhydrocortisone
4-08-00-03498 (Beilstein Handbook Reference)
46436_FLUKA
46436_RIEDEL
570-35-4
6 Methylprednisolone
6.alpha.-Methylprednisolone
6923-42-8
6alpha-Methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione
6alpha-methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
6alpha-Methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
6alpha-Methylprednisolone
6-alpha-Methylprednisolone
6a-Methyl-11b,17a,21-triol-1,4-pregnadiene-3,20-dione
6-Methylprednisolone
6α-methyl-11β,17α,21-triol-1,4-pregnadiene-3,20-dione
83-43-2
AC1L1N7A
Artisone-wyeth
Artisone-Wyeth
Besonia
Bio-0658
BPBio1_000174
BRD-K35240538-001-03-1
BRN 2340300
BSPBio_000158
CHEBI:6888
CHEMBL650
CID6741
CPD000058330
D00407
D008775
DB00959
delta(1)-6alpha-Methylhydrocortisone
Delta(1)-6alpha-Methylhydrocortisone
delta(1)-6a-Methylhydrocortisone
delta(sup 1)-6-alpha-Methylhydrocortisone
Depo-Medrol (acetate)
Dopomedrol
EINECS 201-476-4
Esametone
Firmacort
HMS1568H20
HMS2090B13
HSDB 3127
Lemod
LMST02030178
LS-118498
M0639_SIGMA
M1665
Medesone
Medixon
Medlone 21
Medrate
Medric acid
|
Medrol
Medrol (TN)
Medrol adt pak
Medrol Adt Pak
Medrol dosepak
Medrol Dosepak
Medrol, Solu-Medrol, Medrone, Methylprednisolone
Medrone
MEPRDL
Mesopren
Metastab
Methyleneprednisolone
Methylprednisolon
methylprednisolone
Methylprednisolone
Methylprednisolone (JP15/USP/INN)
Methylprednisolone [USAN:INN:BAN:JAN]
Methylprednisolone, 6-alpha
Methylprednisolonum
Methylprednisolonum [INN-Latin]
methylprenisolone
Metilbetasone
Metilprednisolona
Metilprednisolona [INN-Spanish]
Metilprednisolone
Metilprednisolone [Dcit]
Metilprednisolone [DCIT]
Metipred
Metrisone
Metrocort
Metysolon
MLS000028541
MLS001148159
MLS002207191
Moderin
MolPort-002-528-554
NCGC00022735-03
NCI60_001657
Nirypan
Noretona
NSC19987
NSC-19987
Predni N Tablinen
Prednol- L
Pregna-1,4-diene-3,20-dione, 11beta,17,21-trihydroxy-6alpha-methyl- (8CI)
Prestwick_622
Prestwick0_000279
Prestwick1_000279
Prestwick2_000279
Prestwick3_000279
Promacortine
Reactenol
S1733_Selleck
SAM002589984
Sieropresol
SMR000058330
Solomet
SPBio_002377
Summicort
Suprametil
U 7532
UNII-X4W7ZR7023
Urbason
Urbasone
Wyacort
ZINC03875560
δ(1)-6a-methylhydrocortisone
δ(1)-6α-methylhydrocortisone
|
|
4 |
|
Methylprednisolone hemisuccinate |
Approved |
Phase 4 |
|
2921-57-5 |
|
Synonyms:
Methylprednisolone hydrogen succinate
|
Methylprednisolone succinate
|
|
5 |
|
Prednisolone acetate |
Approved, Vet_approved |
Phase 4 |
|
52-21-1 |
|
6 |
|
Prednisolone |
Approved, Vet_approved |
Phase 4 |
|
50-24-8 |
5755 |
Synonyms:
(11b)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
(11β)-11,17,21-trihydroxypregna-1,4-diene-3,20-dione
.DELTA.1-Cortisol
.DELTA.1-Dehydrocortisol
.DELTA.1-Dehydrohydrocortisone
.DELTA.1-Hydrocortisone
.delta.-Cortef
.delta.-Stab
1,2-Dehydrohydrocortisone
1,4-Pregnadiene-11b,17a,21-triol-3,20-dione
1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione
1,4-pregnadiene-11β,17α,21-triol-3,20-dione
1,4-Pregnadiene-11β,17α,21-triol-3,20-dione
1,4-Pregnadiene-3,20-dione-11b,17a,21-triol
1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol
1,4-pregnadiene-3,20-dione-11β,17α,21-triol
1,4-Pregnadiene-3,20-dione-11β,17α,21-triol
1-Dehydrocortisol
1-Dehydrohydrocortisone
3,20-dioxo-11b,17a,21-Trihydroxy-1,4-pregnadiene
3,20-dioxo-11beta,17alpha,21-Trihydroxy-1,4-pregnadiene
3,20-dioxo-11β,17α,21-trihydroxy-1,4-pregnadiene
46656_FLUKA
46656_RIEDEL
50-24-8
58201-11-9
8056-11-9
AC-1773
AC1L1L2E
Ak-Pred
Ak-Tate
Alphadrol
Articulose-50
Bio-0666
BPBio1_000164
BRD-K98039984-001-03-0
BRN 1354103
BSPBio_000148
Bubbli-Pred
C07369
CCRIS 980
CHEBI:8378
CHEMBL131
CID5755
Codelcortone
Co-Hydeltra
CO-Hydeltra
component of Ataraxoid
component of K-Predne-Dome
Cordrol
Cortalone
Cotogesic
Cotolone
CPD000718761
D00472
D011239
DB00860
Decaprednil
Decortin H
Delcortol
Delta F
delta(1)-Cortisol
delta(1)-Dehydrocortisol
Delta(1)-Dehydrocortisol
delta(1)-Dehydrohydrocortisone
Delta(1)-dehydrohydrocortisone
Delta(1)-Dehydrohydrocortisone
delta(1)-Hydrocortisone
Delta(1)-Hydrocortisone
delta(sup 1)-Cortisol
delta(sup 1)-Dehydrocortisol
delta(sup 1)-Dehydrohydrocortisone
delta(sup 1)-Hydrocortisone
Delta-Cortef
Delta-Cortef (TN)
Deltacortenol
Deltacortril
Deltacortril Enteric
delta-dehydrocortisol
delta-dehydrohydrocortisone
Delta-Ef-Cortelan
delta-hydrocortisone
Deltahydrocortisone
Deltasolone
Delta-stab
Delta-Stab
Deltisilone
Depo-Medrol
Derpo Pd
Derpo PD
Dexa-Cortidelt hostacortin H
Dexa-Cortidelt Hostacortin H
Di adreson F
Di Adreson F
Di-adreson F
Di-Adreson F
Di-adreson-F
DiAdresonF
Di-Adreson-F
Dicortol
Donisolone
Dydeltrone
Eazolin D
Econopred
Econopred Plus
EINECS 200-021-7
Erbacort
Erbasona
Estilsona
Fernisolone
Fernisolone P
Fernisolone-P
Flamasone
HMS1568H10
HMS2090J05
Hostacortin H
HSDB 3385
Hydeltra
Hydeltrasol
Hydeltra-Tba
Hydeltrone
|
Hydrodeltalone
Hydrodeltisone
Hydroretrocortin
Hydroretrocortine
Inflamase Forte
Inflamase Mild
I-Pred
K 1557
Key-Pred
Klismacort
Lentosone
Lite Pred
LMST02030179
LS-7669
Medrol
Medrol Acetate
Metacortandralone
Methylprednisolone acetate
Methylprednisolone Acetate
Meticortelone
Meti-Derm
Metreton
MLS001304083
MLS002154250
MLS002207037
MolPort-002-507-147
M-Predrol
NCGC00179649-01
Neo-Delta-Cortef
Nisolone
Nor-Pred T.B.A.
NSC 9120
NSC9120
NSC9900
Ocu-Pred
Ocu-Pred Forte
Ophtho-Tate
Orapred
P0152_SIGMA
P0637
P6004_SIGMA
Panafcortelone
Paracortol
Paracotol
Pediapred
Poly-Pred
PRDL
Precortalon
Precortancyl
Precortilon
Precortisyl
Pred Forte
Pred Mild
Predair
Predair A
Predair Forte
Predalone 50
Predalone T.B.A.
Predate
Predate Tba
Predate-50
Predcor-25
Predcor-50
Predcor-Tba
PRED-G
Predisolone sodium phosphate
Predisolone Sodium Phosphate
Predne-Dome
Prednelan
Prednicen
Predni-Dome
Predniliderm
Predniretard
Prednis
Prednisolona
Prednisolona [INN-Spanish]
prednisolone
Prednisolone
Prednisolone (anhydrous)
Prednisolone (JP15/USP/INN)
Prednisolone [INN:BAN:JAN]
Prednisolone acetate
Prednisolone Acetate
Prednisolone sodium phosphate
Prednisolone Sodium Phosphate
Prednisolone tebutate
Prednisolone Tebutate
Prednisolonum
Prednisolonum [INN-Latin]
Predonin
Predonine
Prelone
Prenolone
Prestwick_404
Prestwick0_000274
Prestwick1_000274
Prestwick2_000274
Prestwick3_000274
Rolisone
S1737_Selleck
SAM002264639
Scherisolon
SMR000718761
Solone
SPBio_002367
Steran
Sterane
Sterolone
Supercortisol
Ulacort
Ultra Pred
Ultracorten H
Ultracortene H
Ultracortene-H
Ultracortene-hydrogen
Ultracortene-Hydrogen
UNII-9PHQ9Y1OLM
ZINC03833821
δ(1)-dehydrocortisol
δ(1)-dehydrohydrocortisone
δ(1)-hydrocortisone
|
|
7 |
|
Chlorhexidine |
Approved, Vet_approved |
Phase 4 |
|
55-56-1 |
9552079 2713 |
Synonyms:
1,1 inverted exclamation marka-Hexamethylenebis[5-(4-chlorophenyl)biguanide]
1,1'-Hexamethylene bis(5-(p-chlorophenyl)biguanide)
1,1'-Hexamethylene bis(5-(P-chlorophenyl)biguanide)
1,1'-Hexamethylenebis(5-(p-chlorophenyl)biguanide)
1,1'-Hexamethylenebis[5-(4-chlorophenyl)biguanide
1,6-Bis(5-(p-chlorophenyl)biguandino)hexane
1,6-Bis(p-chlorophenyldiguanido)hexane
1,6-Di(4'-chlorophenyldiguanido)hexane
1,6-Di(N-p-chlorophenyldiguanido)hexane
24798_FLUKA
282227_ALDRICH
348031_ALDRICH
4-12-00-01201 (Beilstein Handbook Reference)
55-56-1
AB00053427
AB1003159
AVAGARD
BPBio1_000272
BRN 2826432
BSPBio_000246
BSPBio_001977
C06902
C22H30Cl2N10
CAS-55-56-1
CCRIS 9230
CHEBI:3614
CHEMBL790
Chlorhexidin
Chlorhexidin [Czech]
chlorhexidine
Chlorhexidine
Chlorhexidine (INN)
Chlorhexidine [INN:BAN]
Chlorhexidine Base
Chlorhexidine gluconate
Chlorhexidinum
Chlorhexidinum [INN-Latin]
CID9552079
Cloresidina
Cloresidina [DCIT]
Clorhexidina
Clorhexidina [INN-Spanish]
D07668
DB00878
Decanoylacetaldehyde Sodium Sulfide
Dentisept [veterinary]
Dentisept [veterinary] (TN)
DivK1c_000761
EINECS 200-238-7
Fimeil
Hexadol
Hibiclens
Hibispray
Hibistat
HMS1568M08
HSDB 7196
I06-0621
I14-0050
IDI1_000761
|
KBio1_000761
KBio2_000717
KBio2_003285
KBio2_005853
KBio3_001197
KBioGR_000774
KBioSS_000717
Lisium (*Dihydrochloride*)
LS-43917
Merfen-incolore
Merfen-incolore (TN)
MK-412A
MLS001332387
MLS001332388
MLS002154209
MolPort-002-541-741
N,N'-Bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradeca- nediimidamide
N,N'-bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradecanediimidamide
N,N'-Bis(4-chlorophenyl)-3,12-diimino-2,4,11,13-tetraazatetradecanediimidamide
N,N''''-hexane-1,6-diylbis[N'-(4-chlorophenyl)(imidodicarbonimidic diamide)]
N',N'''''-hexane-1,6-diylbis[N-(4-chlorophenyl)(imidodicarbonimidic diamide)]
NCGC00016246-01
NCGC00091025-01
NCGC00091025-02
NINDS_000761
Nolvasan
Nolvasan (*Diacetate*)
Novalsan
NSC526936
Oro-Clense
Peridex
Periogard
Prestwick_53
Prestwick0_000143
Prestwick1_000143
Prestwick2_000143
Prestwick3_000143
QTL1_000020
Rotersept
Savloclens
Savlon babycare
Sebidin A
SMR000857146
Sodium Houttuyfonamide
Soretol
SPBio_000210
SPBio_002185
Spectrum_000237
Spectrum2_000135
Spectrum3_000339
Spectrum4_000277
Spectrum5_001322
Sterido
Sterilon
STK089248
STOCK1S-18831
Superspray
Tubulicid
UNII-R4KO0DY52L
|
|
8 |
|
Ceftriaxone |
Approved |
Phase 4 |
|
73384-59-5 |
5361919 5479530 |
Synonyms:
(6R,7R)-7-({(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(methyloxy)imino]acetyl}amino)-3-{[(6-hydroxy-2-methyl-5-oxo-2,5-dihydro-1,2,4-triazin-3-yl)thio]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-8-oxo-3-(((1,2,5,6-tetrahydro-2-methyl-5,6-dioxo-as-triazin-3-yl)thio)methyl)-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7(sup 2)-(Z)-(O-methyloxime), sesquaterhydrate
(6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(2-methyl-5,6-dioxo-1H-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
(6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulphanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
(6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulphanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
104376-79-6
104376-79-6 (di-hydrochloride salt)
73384-59-5
74578-69-1 (di-hydrochloride salt, hemiheptahydrate)
7beta-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-3,4-didehydrocepham-4-carboxylic acid
AC-1592
AC1NUIFE
Anhydrous ceftriaxone sodium
Benaxona
Biotrakson
Boehringer mannheim brand OF ceftriaxone sodium
C06683
C18H18N8O7S3
Cefatriaxone
Cefaxona
Ceftrex
Ceftriaxon
Ceftriaxon curamed
Ceftriaxon hexal
Ceftriaxona
Ceftriaxona [INN-Spanish]
Ceftriaxona andreu
Ceftriaxona LDP torlan
ceftriaxone
Ceftriaxone
Ceftriaxone (INN)
Ceftriaxone (TN)
Ceftriaxone [USAN:JAN]
Ceftriaxone intravenous
Ceftriaxone irex
Ceftriaxone sodium
CEFTRIAXONE SODIUM
Ceftriaxone sodium, anhydrous
Ceftriaxone, disodium salt
Ceftriaxone, Disodium Salt
|
Ceftriaxone, disodium salt, hemiheptahydrate
Ceftriaxone, Disodium Salt, Hemiheptahydrate
Ceftriaxonum
Ceftriaxonum [INN-Latin]
Ceftriazone
CHEBI:29007
CHEMBL161
CID5479530
Columbia brand OF ceftriaxone
CTRX
Curamed brand OF ceftriaxone sodium
D07659
DB01212
DRG-0071
EINECS 277-405-6
Fustery brand OF ceftriaxone sodium
Galen brand OF ceftriaxone sodium
Hexal brand OF ceftriaxone sodium
Hoffman la roche brand OF ceftriaxone sodium
Hoffman-la roche brand OF ceftriaxone sodium
Inibsa brand OF ceftriaxone sodium
Irex brand OF ceftriaxone
Lendacin
Longacef
Longaceph
LS-150031
MolPort-005-933-495
Pisa brand OF ceftriaxone sodium
Ro 139904
Ro13-9904
Ro-13-9904
Rocefalin
Rocefin
Rocephin
Rocephine
Roche brand OF ceftriaxone sodium
Sodium, ceftriaxone
Syntex brand OF ceftriaxone sodium
Tacex
Terbac
UNII-75J73V1629
|
|
9 |
|
Strawberry |
Approved |
Phase 4 |
|
|
|
10 |
|
Olodaterol |
Approved |
Phase 4 |
|
868049-49-4 |
|
Synonyms:
|
11 |
|
Budesonide |
Approved |
Phase 4 |
|
51333-22-3 |
63006 5281004 |
Synonyms:
(11b,16a)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
(11beta,16alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
(11-beta,16-alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
(11β,16α)-16,17-(butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
(11β,16α)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione
(4aR,4bS,5S,6aS,6bS,8R,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one
(4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one
(R,S)-11b,16a,17,21,tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with buty raldehyde
(RS)-(11beta,16alpha)-16,17-[Butylidenebis(oxy)]-11,21-dihydroxypregna-1,4-diene-3,20-dione
(RS)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with butyraldehyde
(S)-16alpha,17-(Butylidenedioxy)-11beta,21-dihydroxypregna-1,4-diene-3,20-dione
11beta,21-dihydroxy-16alpha,17alpha-(butane-1,1-diyldioxy)pregna-1,4-diene-3,20-dione
16,17-Butylidenebis(oxy)-11,21-dihydroxypregna-1,4-diene-3,20-dione
16,17-Butylidenebis(oxy)-11-,21-dihydroxypregna-1,4-diene-3,20-dione
16alpha(R),17-(Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione
16-alpha,17-alpha-Butylidenedioxy-11-beta,21-dihydroxy-1,4-pregnadiene-3,20-dione
16alpha-,17alpha--butylidenedioxypregna-1,4-diene-11beta-,21-diol-3,20-dione
51333-22-3
AC1L1DQE
AC1L1Y6Y
AC1L22VC
AC1MHWI7
AC-4697
B 7777
B7777_SIGMA
Bidien
Bio-0010
BPBio1_000523
BRD-A34299591-001-03-4
BRD-A82238138-001-01-7
BSPBio_000475
BSPBio_002160
Budecort Inhaler
Budenofalk
Budeson
Budesónida
budesonide
Budesonide
Budesonide (JAN/USAN/INN)
Budesonide [USAN:INN:BAN:JAN]
Budesonide Easyhaler
Budesonide MMX
Budesonide, (R)-isomer
Budesonide, (S)-isomer
Budesonido
Budesonido [INN-Spanish]
Budesonidum
Budesonidum [INN-Latin]
Budiair
Budicort
C25H34O6
CCRIS 5230
CHEBI:3207
CHEBI:656601
CHEMBL1370
CID2462
CID3033890
CID40000
CID5281004
CID63006
Cortivent
CPD000058337
D00246
DB01222
Desowen
Dexbudesonide
Dexbudesonide [INN]
DivK1c_000475
EINECS 257-139-7
EINECS 257-160-1
EINECS 257-161-7
Entocort
Entocort EC
Entocort EC (TN)
EU-0100174
Giona Easyhaler
HMS1569H17
|
HMS1921I22
HMS2094I13
HMS501H17
Horacort
IDI1_000475
Inflammide
KBio1_000475
KBio3_001660
KBioGR_001361
Lopac0_000174
LS-187734
LS-7235
MAP-0010
Micronyl
Miflonide
MLS000028507
MLS001077323
MLS002207112
MolPort-002-529-265
MolPort-003-666-332
MolPort-003-986-909
NCGC00015165-03
NCGC00021318-03
NCGC00021318-06
NCGC00089747-02
NCGC00089747-03
NCGC00089747-04
NCGC00178789-01
NINDS_000475
Noex
Preferid
Pregna-1,4-diene-3,20-dione, 16,17-butylidenebis(oxy)-11,21-dihydroxy-, (11beta,16alpha(R))-, and 16alpha,17-((S)-Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione
Prestwick_840
Prestwick0_000518
Prestwick1_000518
Prestwick2_000518
Prestwick3_000518
Pulmaxan
Pulmaxan turbohaler
Pulmicort
Pulmicort (TN)
Pulmicort Flexhaler
Pulmicort Nebuamp
Pulmicort Respules
Pulmicort Topinasal
Pulmicort turbuhaler
Pulmicort Turbuhaler
Respules
Rhinocort
Rhinocort alpha
Rhinocort Aqua
Rhinocort Turbuhaler
Rhinocort, Pulmicort , Entocort, Symbicort, Noex. Entocort EC, Budesonide
Rhinosol
S 1320
S1286_Selleck
S-1320
SAM002699898
SMR000058337
SPBio_000586
SPBio_002396
SPECTRUM1500813
Spectrum2_000623
Spectrum3_000620
Spectrum4_000821
Spectrum5_001738
Spirocort
ST51039033
TL8003397
Tridesilon
UDB
UNII-168L5HT37P
UNII-2HI1006KPH
UNII-Q3OKS62Q6X
Unit dose budesonide
ZINC03938751
ZINC04097286
|
|
12 |
|
Prednisolone hemisuccinate |
Experimental |
Phase 4 |
|
2920-86-7 |
|
Synonyms:
(+)-prednisolone hemisuccinate
Prednisolonbisuccinat
Prednisolone 21-hemisuccinate
Prednisolone 21-succinate
|
Prednisolone bisuccinate
Prednisolone hydrogen succinate
Prednisolone succinate
|
|
13 |
|
Chlorine dioxide |
Investigational |
Phase 4 |
|
10049-04-4 |
|
14 |
|
Anti-Inflammatory Agents |
|
Phase 4 |
|
|
|
15 |
|
Methylprednisolone Acetate |
|
Phase 4 |
|
|
|
16 |
|
Antineoplastic Agents, Hormonal |
|
Phase 4 |
|
|
|
17 |
|
Antitoxins |
|
Phase 4 |
|
|
|
18 |
|
Aluminum phosphate |
|
Phase 4 |
|
|
|
19 |
|
Chlorhexidine gluconate |
|
Phase 4 |
|
|
|
20 |
|
Anti-Infective Agents, Local |
|
Phase 4 |
|
|
|
21 |
|
Disinfectants |
|
Phase 4 |
|
|
|
22 |
|
Micronutrients |
|
Phase 4 |
|
|
|
23 |
|
Trace Elements |
|
Phase 4 |
|
|
|
24 |
|
Parasympatholytics |
|
Phase 4 |
|
|
|
25 |
|
Cholinergic Agents |
|
Phase 4 |
|
|
|
26 |
|
Tiotropium Bromide |
|
Phase 4 |
|
136310-93-5 |
|
27 |
|
Cholinergic Antagonists |
|
Phase 4 |
|
|
|
28 |
|
Adrenergic beta-Agonists |
|
Phase 4 |
|
|
|
29 |
|
Hormones |
|
Phase 4 |
|
|
|
30 |
|
Salmeterol xinafoate |
|
Phase 4 |
|
94749-08-3 |
56801 |
Synonyms:
(+-)-4-Hydroxy-alpha(sup 1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-m-xylene-alpha,alpha'-diol 1-hydroxy-2-naphthoate (salt)
(+/-) 4-Hydroxy-a1-[[[6-(4-phenylbutoxy)hexyl]amino]m-ethyl]-1,3-benzenedimethanol xinafoate
1,3-Benzenedimethanol, 4-hydroxy-alpha(sup 1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-, (+-)-, 1-hydroxy-2-naphthalenecarboxylate (salt)
1-hydroxynaphthalene-2-carboxylic acid
2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]ethyl]phenol
89365-50-4 (Parent)
94749-08-3
AC1L1LPS
Arial
Asmerole
Beglan
Betamican
Bio-0096
C25H37NO4.C11H8O3
CHEMBL1082607
CID56801
D00687
Dilamax
EU-0101100
GR 33343 G
GR 33343X xinafoate
GR-33343 G
|
Inaspir
LS-94516
MLS001332577
MLS001332578
MolPort-003-850-218
NCGC00094372-01
NCGC00094372-02
NCGC00094372-03
NCGC00094372-04
S5068_SIGMA
Salmetedur
Salmeterol 1-hydroxy-2-naphthoate
salmeterol xinafoate
Salmeterol xinafoate (JAN/USAN)
Salmeterol xinafoate [USAN]
Serevent (TN)
Serevent diskus
Serevent Inhaler and Disks
SMR000875207
Ultrabeta
UNII-6EW8Q962A5
|
|
31 |
|
Adrenergic Agents |
|
Phase 4 |
|
|
|
32 |
|
Formoterol Fumarate |
|
Phase 4 |
|
|
|
33 |
|
Hormone Antagonists |
|
Phase 4 |
|
|
|
34 |
|
Fluticasone-Salmeterol Drug Combination |
|
Phase 4 |
|
|
|
35 |
|
glucocorticoids |
|
Phase 4 |
|
|
|
36 |
|
Anticonvulsants |
|
Phase 4 |
|
|
|
37 |
|
Sympathomimetics |
|
Phase 4 |
|
|
|
38 |
|
Bromides |
|
Phase 4 |
|
|
|
39 |
|
Neurotransmitter Agents |
|
Phase 4 |
|
|
|
40 |
|
Adrenergic Agonists |
|
Phase 4 |
|
|
|
41 |
|
Gemifloxacin |
Approved, Investigational |
Phase 3 |
|
175463-14-6 |
5464436 9571107 |
Synonyms:
175463-14-6
204519-64-2
210353-52-9
210353-53-0
210353-55-2
210353-56-3
214346-11-9
7-(3-Aminomethyl)-4-methoxyimino-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid
7-(3-Aminomethyl-4-methoxyimino-pyrrolidine-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-(1,8)-naphthyridine-3-carboxylic acid
7-[3-(aminomethyl)-4-(methoxyimino)pyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
BRD-A40787240-066-02-0
BSPBio_002308
CHEBI:101853
CHEMBL430
CID9571107
D08012
|
Factiv
Factiv (TN)
Factive
Gemifloxacin
Gemifloxacin (INN)
Gemifloxacin [INN]
Gemifloxacin mesilate
Gemifloxacin mesylate
LB 20304
LB 20304a
LB-20304
LS-186992
LS-187779
NCGC00178711-01
SB 265805
SB-265805
|
|
42 |
|
Rabeprazole |
Approved, Investigational |
Phase 3 |
|
117976-89-3 |
5029 |
Synonyms:
117976-89-3
1H-Benzimidazole, 2-(((4-(3-methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)-, sodium salt
2-(((4-(3-Methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole
2-((4-(3-methoxypropoxy)-3-methylpyridin-2-yl)methylsulfinyl)-1H-benzimidazole
2-((4-(3-Methoxypropoxy)-3-methylpyridin-2-yl)methylsulfinyl)-1H-benzimidazole
2-({[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methyl}sulfinyl)-1H-benzimidazole
2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]-1H-benzimidazole
AC1L1JGC
Aciphex
AcipHex
BIDD:GT0019
C063129
C07864
C18H21N3O3S
CHEBI:8768
CHEMBL1219
CID5029
CL23619
Clofezone
CPD000469174
D08463
DB01129
dexrabeprazole
Dexrabeprazole
Eraloc
|
Eraloc (TN)
Habeprazole
HMS2052P03
HSDB 7321
I06-0755
Irsogladine Maleate
LS-172365
LY307640
MLS001401446
MolPort-005-935-061
Pariet
Pariets
rabeprazole
Rabeprazole
Rabeprazole (INN)
Rabeprazole [BAN:INN]
Rabeprazole [INN:BAN]
rabeprazole sodium
Rabeprazole sodium
Rebeprazole sodium
SAM001246619
SMR000469174
Sodium rabeprazole
Sodium, rabeprazole
UNII-32828355LL
|
|
43 |
|
Moxifloxacin |
Approved, Investigational |
Phase 3 |
|
354812-41-2, 151096-09-2 |
152946 |
Synonyms:
(1'S,6'S)-1-Cyclopropyl-7-(2,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
151096-09-2
186826-86-8
192927-63-2
1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4as,7as)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-3-quinolinecarboxylate
1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4as,7as)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-3-quinolinecarboxylic acid
1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-((4aS,7aS)-octahydro-6H-pyrrolo(3,4-b)pyridin-6-yl)-4-oxo-3-quinolinecarboxylic acid
1-Cyclopropyl--7-(2,8-diazabicyclo(4.3.0)non-8-yl)-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid
7-[(4aS,7aS)-1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3-carboxylic acid
AC1L49EP
Actira
Actira (*Hydrochloride*)
Avalox
Avelox
Avelox (*Hydrochloride*)
Avelox I.V.
BAY 12-8039
BAY 12-8039 (*Hydrochloride*)
CCRIS 8690
|
CHEMBL32
CID152946
DB00218
I06-1961
Izilox
LS-141510
MFX
moxifloxacin
Moxifloxacin
Moxifloxacin [INN:BAN]
Moxifloxacin HCl
Moxifloxacin hydrochloride
Moxifloxacino
MXF
MXFX
Octegra
Proflox
UNII-U188XYD42P
Vigamox
|
|
44 |
|
tannic acid |
Approved |
Phase 3 |
|
1401-55-4 |
|
Synonyms:
ácido tánico
Gallotannic acid
|
|
|
45 |
|
Benzocaine |
Approved, Investigational |
Phase 3 |
|
94-09-7, 1994-09-7 |
2337 |
Synonyms:
(P-(Ethoxycarbonyl)phenylamine
06952_FLUKA
112909_ALDRICH
112909_SIAL
1333-08-0
23239-88-5
23239-88-5 (hydrochloride)
4 Aminobenzoic Acid Ethyl Ester
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-14-00-01129 (Beilstein Handbook Reference)
4-Aminobenzoate
4-Aminobenzoate ethyl ester
4-Aminobenzoic acid
4-aminobenzoic acid ethyl ester
4-amino-benzoic acid ethyl ester
4-Aminobenzoic acid ethyl ester
4-Aminobenzoic acid, ethyl ester
4-Carbethoxyaniline
71123-91-6
94-09-7
94-09-7 (Parent)
A0271
AB00051923
AC1L1DGC
AC1Q341A
AC1Q64JE
Acetate, benzocaine
Acetate, Benzocaine
AE-562/40377256
Aethoform
Aethylium paraminobenzoicum
AI3-02081
AKOS000119763
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthesinum
Anaesthin
Anestezin
Anestezin [Russian]
Anesthesin
Anesthesine
Anesthone
AR-1H9065
Baby anbesol
Baby Anbesol
BB_SC-0019
Bensokain
Benzoak
Benzocaina
Benzocaina [INN-Spanish]
benzocaine
Benzocaine
Benzocaine (USP/INN)
Benzocaine [INN:BAN]
Benzocaine acetate
Benzocaine Acetate
Benzocaine formate
Benzocaine Formate
Benzocaine hydrobromide
Benzocaine Hydrobromide
Benzocaine hydrochloride
Benzocaine Hydrochloride
Benzocaine methanesulfonate
Benzocaine Methanesulfonate
Benzocainum
Benzocainum [INN-Latin]
Benzoic acid, 4-amino-, ethyl ester
Benzoic acid, 4-amino-, ethyl ester, hydrochloride
Benzoic acid, amino-, ethyl ester
Benzoic acid, p-amino-, ethyl ester
BPBio1_001017
BRD-K75466013-001-05-2
BRN 0638434
BSPBio_000923
BSPBio_001908
C07527
CAS-94-09-7
Caswell No. 430A
CHEBI:116735
CHEMBL278172
Chloraseptic
CID2337
D001566
D00552
DB01086
Dermoplast
Diet ayds
DivK1c_000932
E1501_SIGMA
EINECS 202-303-5
EPA Pesticide Chemical Code 097001
Ethoform
Ethoforme
Ethyl 4-aminobenzoate
Ethyl 4-aminobenzoate hydrochloride
Ethyl 4-aminobenzoic acid
Ethyl aminobenzoate
Ethyl aminobenzoate (JP15)
Ethyl aminobenzoate (VAN)
|
Ethyl aminobenzoic acid
Ethyl PABA
Ethyl P-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl P-aminobenzoate
Ethyl P-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethyl P-aminophenylcarboxylate
Ethyl P-aminophenylcarboxylic acid
ethylaminobenzoate-4
Ethylester kyseliny p-aminobenzoove
Ethylester kyseliny P-aminobenzoove
Ethylester kyseliny p-aminobenzoove [Czech]
Ethylis aminobenzoas
ETHYL-P-AMINOBENZOATE
Formate, benzocaine
Formate, Benzocaine
h-4-abz-oet
HMS1570O05
HMS1920G09
HMS2091M11
HMS502O14
HSDB 7225
Hurricaine
Hydrobromide, benzocaine
Hydrobromide, Benzocaine
Hydrochloride, benzocaine
Hydrochloride, Benzocaine
I05-0204
Identhesin
IDI1_000932
KBio1_000932
KBio2_000474
KBio2_003042
KBio2_005610
KBio3_001408
KBioGR_000658
KBioSS_000474
Keloform
LS-35847
Methanesulfonate, benzocaine
Methanesulfonate, Benzocaine
MLS001331704
MLS002153970
MolPort-000-871-526
NCGC00016352-01
NCGC00094598-01
NCGC00094598-02
nchembio.182-comp4
NINDS_000932
Norcain
Norcaine
Norcainum
NSC 122792
NSC 41531
NSC41531
NSC4688
Oprea1_750694
Oprea1_827402
Orabase-b
Ora-jel
Orthesin
Otocain
Outgro
p-(Ethoxycarbonyl)aniline
P-(Ethoxycarbonyl)aniline
P-Aminobenzoate
P-Aminobenzoic acid
p-Aminobenzoic acid ethyl ester
P-Aminobenzoic acid ethyl ester
p-Aminobenzoic acid, ethyl ester
p-Aminobenzoic ethyl ester
Parathesin
Parathesin (TN)
Parathesine
p-Carbethoxyaniline
P-Carbethoxyaniline
p-Ethoxycarboxylic aniline
P-Ethoxycarboxylic aniline
Prestwick_991
Prestwick0_000712
Prestwick1_000712
Prestwick2_000712
Prestwick3_000712
Slim mint gum
SMR000059025
Solarcaine
Solu H
SPBio_000134
SPBio_002844
Spectrum_000074
SPECTRUM1500139
Spectrum2_000117
Spectrum3_000314
Spectrum4_000249
Spectrum5_000860
STK043620
Topcaine
UNII-U3RSY48JW5
WLN: ZR DVO2
ZINC12358719
|
|
46 |
|
Edetic Acid |
Approved, Vet_approved |
Phase 3 |
|
60-00-4, 62-33-9 |
6049 |
Synonyms:
(ethylenedinitrilo)Tetraacetate, ion(4-)
(ethylenedinitrilo)tetraacetic acid, ion(4−)
(ethylenedinitrilo)Tetraacetic acid, ion(4-)
{[-(bis-carboxymethyl-amino)-ethyl]-carboxymethyl-amino}-acetate
{[-(bis-carboxymethyl-amino)-ethyl]-carboxymethyl-amino}-acetic acid
{[-(bis-carboxymethyl-amino)-ethyl]-carboxymethyl-amino}-acetIC ACID
2,2',2'',2'''-(ethane-1,2-diyldinitrilo)tetraacetate
2,2',2'',2'''-(ethane-1,2-diyldinitrilo)tetraacetic acid
Acid, edetic
Acid, ethylenediaminetetraacetic
Acid, ethylenedinitrilotetraacetic
Acide edetique
Acide ethylenediaminetetracetique
acido Edetico
Acido edetico
Acidum edeticum
CaEDTA
Calcitetracemate, disodium
Calcium disodium edetate
Calcium disodium versenate
Calcium tetacine
Chelaton 3
Chromium edta
Copper edta
Coprin
Dicobalt edta
Dinitrilotetraacetate, disodium ethylene
Dinitrilotetraacetate, ethylene
Disodium calcitetracemate
Disodium edta
Disodium ethylene dinitrilotetraacetate
Disodium versenate, calcium
Distannous edta
Edathamil
Edetate
Edetate calcium
Edetate calcium disodium
Edetate disodium calcium
Edetate, calcium disodium
Edetates
Edetic acid
Edetic acid, calcium salt
|
Edetic acid, calcium, sodium salt
Edetic acid, chromium salt
Edetic acid, dipotassium salt
Edetic acid, disodium salt
Edetic acid, disodium salt, dihydrate
Edetic acid, disodium, magnesium salt
Edetic acid, disodium, monopotassium salt
Edetic acid, magnesium salt
Edetic acid, monopotassium salt
Edetic acid, monosodium salt
Edetic acid, potassium salt
Edetic acid, sodium salt
EDT
EDTA
EDTA, chromium
EDTA, copper
EDTA, dicobalt
EDTA, disodium
EDTA, distannous
EDTA, gallium
EDTA, ion(4-)
EDTA, magnesium disodium
EDTA, potassium
EDTA, stannous
Ethylene dinitrilotetraacetate
Ethylene dinitrilotetraacetate, disodium
Ethylenediaminetetraacetate
Ethylenediaminetetraacetic acid
Ethylenedinitrilotetraacetic acid
Gallium edta
H4EDta
Magnesium disodium edta
N,N'-1,2-ethane diylbis-(N-(carboxymethyl)glycine)
N,N'-1,2-Ethane diylbis-(N-(carboxymethyl)glycine)
N,N'-1,2-ethanediylbis(N-(carboxymethyl)glycine)
Potassium edta
Stannous edta
Tetacine, calcium
Tetracemate
Versenate
Versenate, calcium disodium
Versene
|
|
47 |
|
Iron |
Approved, Experimental |
Phase 3 |
|
15438-31-0, 7439-89-6 |
27284 23925 |
Synonyms:
02583_FLUKA
12310_ALDRICH
12310_RIEDEL
129048-51-7
14067-02-8
161135-39-3
190454-13-8
195161-83-2
199281-22-6
209309_ALDRICH
209309_SIAL
255637_ALDRICH
266213_ALDRICH
266256_ALDRICH
267945_ALDRICH
267953_ALDRICH
26Fe
338141_ALDRICH
356808_ALDRICH
356824_ALDRICH
356832_ALDRICH
39344-71-3
3ZhP
413054_ALDRICH
443783-52-6
44890_ALDRICH
44890_FLUKA
675141-17-0
70884-35-4
73135-38-3
7439-89-6
8011-79-8
8053-60-9
AC1L2N38
Ancor B
Ancor en 80/150
armco Iron
Armco iron
Atomel 28
Atomel 300M200
Atomel 500M
Atomel 95
Atomiron 44MR
Atomiron 5M
Atomiron AFP 25
Atomiron AFP 5
ATW 230
ATW 432
C00023
C3518_SIAL
C3518_SIGMA
Carbonyl iron
CCRIS 1580
CHEBI:18248
CID23925
Copy Powder CS 105-175
D007501
DB01592
Diseases (animal), iron overload
Diseases, iron overload
DSP 1000
DSP 128B
DSP 135
DSP 135C
DSP 138
Ed-In-Sol
EF 1000
EF 250
EFV 200/300
EFV 250
EFV 250/400
EINECS 231-096-4
Eisen
Electrolytic iron
F 60 (metal)
Fe
FE
FE (II) ion
Fe(2+)
Fe(II)
Fe1+
Fe2+
Fe-40
|
fer
Feronate
Ferretts
Ferro-Caps
Ferro-Time
Ferrous ion
ferrous iron
Ferrousal
Ferrovac e
Ferrovac E
Ferrum
Ferrum metallicum
FT 3 (element)
GS 6
Hematite
Hemocyte
HF 2 (element)
hierro
Hierro
HL (iron)
Hoeganaes ATW 230
Hoeganaes EH
HQ (metal)
HS (iron)
HS 4849
HSDB 604
Infed
IRMM524A_FLUKA
IRMM524B_FLUKA
IRON
Iron (Fe)
Iron (Fe1+)
Iron ion (Fe+)
Iron ion(1+)
Iron ion(2+)
Iron monocation
Iron powder
Iron standard for AAS
Iron(1+)
Iron(1+) ion
Iron(2+)
Iron(2+) ion
Iron(II) ion
Iron(III) nitrate solution
Iron, carbonyl
Iron, electrolytic
Iron, elemental
Iron, ion (Fe1+)
Iron, ion (Fe1+) (8CI,9CI)
Iron, ion (Fe2+)
Iron, reduced
Limonite
LOHA
LS-3196
Magnetite
Malleable iron
Metopirone
Metyrapone
MolPort-003-925-001
NC 100
PZh1M1
PZh-1M3
PZh-2
PZh2M
PZH2m
PZh2M1
PZh2M2
PZh3
PZh3M
PZh4M
PZhO
PZHO
Reduced iron
Remko
Siderol
Suy-b 2
SUY-B 2
Taconite
UNII-E1UOL152H7
Venofer
Vitedyn-Slo
Wrought iron
Yieronia
|
|
48 |
|
Pentetic acid |
Approved |
Phase 3 |
|
67-43-6 |
|
Synonyms:
Diethylene triamine pentaacetic acid
Diethylenetriamine pentaacetic acid
Diethylenetriaminepentaacetate
Diethylenetriaminepentaacetic acid
|
DTPA
DTP-A
Pentetate
Pentetic acid
|
|
49 |
|
Deferiprone |
Approved |
Phase 3 |
|
30652-11-0 |
2972 |
Synonyms:
1,2-Dimethyl-3-hydroxypyrid-4-one
3-Hydroxy-1,2-dimethyl-4(1H)-pyridone
Deferiprona
|
Deferiprone
Défériprone
Deferipronum
|
|
50 |
|
Aluminum hydroxide |
Approved, Investigational |
Phase 3 |
|
21645-51-2 |
|
Synonyms:
Aluminio hidróxido
Aluminium hydroxide
Aluminium hydroxide gel, dried
Aluminium hydroxide, dried
|
Aluminum hydroxide gel, dried
Aluminum hydroxide, dried
Dried aluminium hydroxide
Dried aluminum hydroxide gel
|
|
Interventional clinical trials:
(show top 50)
(show all 265)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Open Label Multicentric Randomized Phase IV Post Marketing Safety, Immunogenicity and Lot-to-Lot Consistency Analysis of Shan 5 [DTPwHB-Hib (Liquid) Pentavalent Combination Vaccine] in Indian Infants |
Unknown status |
NCT00877357 |
Phase 4 |
|
2 |
Clinical Relevance of Middle Meatal Bacteriology During Acute Respiratory Infection in Children - Randomised, Double-Blinded Clinical Study |
Unknown status |
NCT00545961 |
Phase 4 |
placebo;amoxicillin clavulanate acid |
3 |
Temocillin Pharmacokinetics in Paediatrics |
Unknown status |
NCT02260102 |
Phase 4 |
Temocillin |
4 |
Efficacy of Systemic Glucocorticoid in the Treatment of Wheezing in Children |
Unknown status |
NCT00494624 |
Phase 4 |
prednisolone |
5 |
Phase 4 Study of Haemophilus Influenzae Type b Vaccine in Different Injection Site |
Completed |
NCT01761136 |
Phase 4 |
|
6 |
The Immediate and Longterm Immune Responses of UK Infants and Young Children to a Booster Dose of Hib Vaccine |
Completed |
NCT00197782 |
Phase 4 |
|
7 |
An Open Label Multicentric Study to Evaluate the Immunogenicity and Safety of Indigenously Developed DTPwHB-Hib (Liquid) Pentavalent Combination Vaccine (Shan 5) in Indian Infants. |
Completed |
NCT00617812 |
Phase 4 |
|
8 |
Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand |
Completed |
NCT00255021 |
Phase 4 |
|
9 |
Assess the Safety & Reactogenicity of GSK Biologicals Hib Vaccine Co-administered With Chinese Local DTPw Vaccine When Compared to Chinese Local DTPw Vaccine Administered Alone, in Healthy Infants at 3,4 & 5 Mths of Age |
Completed |
NCT00158795 |
Phase 4 |
|
10 |
A Single Blind, Multicentric, Comparative, Vaccine Interchangeability Trial of Shan 5 (Liquid) and Easy Five (Liquid) [Diphtheria-Tetanus- Pertussis, Hepatitis B and Hib Pentavalent Combination Vaccines] in Indian Infants. |
Completed |
NCT00674908 |
Phase 4 |
|
11 |
A Post Marketing Surveillance Study to Monitor the Reactogenicity and Safety of Vaxemâ„¢Hib When Administered According to the Prescribing Information in Korea |
Completed |
NCT01404962 |
Phase 4 |
|
12 |
A Demonstration Project for the Elimination of Haemophilus Influenzae Type B in Three Rural Alaska Native Villages |
Completed |
NCT00153556 |
Phase 4 |
|
13 |
Pneumococcal Conjugate Vaccine (PCV) Schedules for the Northern Territory (NT): Randomised Controlled Trial of Booster Vaccines to Broaden and Strengthen Protection From Invasive and Mucosal Infections. |
Completed |
NCT01735084 |
Phase 4 |
|
14 |
A Randomized Clinical Trial on the Effect of a Chlorine Dioxide Spray on Dental Plaque and Respiratory Pathogens in Institutionalized Elders |
Completed |
NCT03533335 |
Phase 4 |
|
15 |
Safety and Immunogenicity of DAPTACEL® (CP10/5/5/3DT Aventis Pasteur 5-component Pertussis Vaccine in Combination With Tetanus and Diphtheria Toxoids Adsorbed) Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACELâ„¢ (HCP20/20/5/3DT-mIPV//PRP-T) |
Completed |
NCT00802867 |
Phase 4 |
|
16 |
A Phase IV, Single-blind, Randomized, Controlled, Monocentric Study to Assess the Interchangeability of Quinvaxem (DTwP-HepB-Hib) as the 2nd and 3rd Dose After Initial Vaccination With Tritanrix HB+Hib (DTwP-HepB/Hib) With Respect to Safety and Immunogenicity in Healthy Infants at 6, 10 and 14 Weeks of Age |
Completed |
NCT01357720 |
Phase 4 |
|
17 |
Safety of the DTacP-IPV//PRP~T Combined Vaccine (PENTAXIM®) Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China |
Completed |
NCT01491087 |
Phase 4 |
|
18 |
Assessment of Long-term Antibody Persistence After a Booster Dose of GSK Biologicals' Hib & Meningococcal C Vaccine (Menitorixâ„¢) 811936 Given at 12-15 Months of Age to Subjects Primed With 3 Doses of Menitorixâ„¢ at 2, 3, 4 Months of Age |
Completed |
NCT00454987 |
Phase 4 |
|
19 |
Immunogenicity and Safety Study of GSK Biologicals' Combined Diphtheria-tetanus-acellular Pertussis-hepatitis B-inactivated Polio-virus and Haemophilus Influenzae Type b Vaccine (Infanrix Hexaâ„¢) (217744) in Healthy Infants Born to Mothers Vaccinated With Boostrixâ„¢ During Pregnancy or Immediately Post-delivery |
Completed |
NCT02422264 |
Phase 4 |
Prevnar13 |
20 |
An Open-Label Multi-Center Study of Eculizumab in Children and Adolescents With a Diagnosis of Paroxysmal Nocturnal Hemoglobinuria |
Completed |
NCT00867932 |
Phase 4 |
Eculizumab |
21 |
A Randomised Controlled Trial of Pneumococcal Conjugate Vaccines Synflorix and Prevenar13 in Sequence or Alone in High-risk Indigenous Infants (PREV-IX_COMBO): Immunogenicity, Carriage and Otitis Media Outcomes |
Completed |
NCT01174849 |
Phase 4 |
Synflorix;Prevenar13;COMBO |
22 |
Pneumonia in Children: Aetiology, Ideal Antibiotic Duration, Quality of Life |
Completed |
NCT02258763 |
Phase 4 |
Amoxicillin-Potassium Clavulanate Combination;Placebo |
23 |
A Phase IV Study to Evaluate the Primary and Booster Immune Responses of UK Infants Receiving a Licensed 6-in-1 DTaP/IPV/Hib/HBV Vaccine (Infanrix-HexaTM) With a 13-valent Pneumococcal Conjugate Vaccine and Incorporating a Randomisation Study of a Single Dose of 3 Different Meningococcal Group C Conjugate Vaccines at 3 Months of Age |
Completed |
NCT01896596 |
Phase 4 |
|
24 |
Randomized, Controlled Clinical Trial of Day-care Based and Hospitalized Management of Severe and Very Severe Pneumonia, With Severe Malnutrition, With/Without Associated Co-morbidities in Children |
Completed |
NCT00968370 |
Phase 4 |
|
25 |
Efficacy of Antimicrobials in Young Children With Acute Otitis Media (AOM) |
Completed |
NCT00377260 |
Phase 4 |
amoxicillin-clavulanate;Placebo |
26 |
A Randomised Controlled Trial Comparing Two-Dose Priming With the 10-Valent Pneumococcal Conjugate Vaccine at 6 and 10 Weeks to 6 and 14 Weeks in Nepali Children |
Completed |
NCT02385513 |
Phase 4 |
|
27 |
INvestigating COPD Outcomes, Genomics and Neutrophilic Inflammation With Tiotropium and Olodaterol |
Recruiting |
NCT03152149 |
Phase 4 |
Tiotropium & olodaterol;fluticasone furoate & vilanterol |
28 |
Vaccinating Children After Chemotherapy for Acute Lymphoblastic Leukemia: A Canadian Immunization Research Network Study |
Active, not recruiting |
NCT02447718 |
Phase 4 |
|
29 |
Babies Born Early Antibody Response to Men B Vaccination: A Phase IV Multicentre Randomised Study to Evaluate the Primary and Booster Immune Responses in UK Preterm Infants Receiving Routine Immunisations and Incorporating a Three Dose Versus a Two Dose Schedule of 4CMenB (Bexsero®) for Primary Immunisation. |
Active, not recruiting |
NCT03125616 |
Phase 4 |
|
30 |
Investigating the Mechanism of Inhaled Corticosteroids Associated Pneumonia by Longitudinal Characterisation of the Airway Microbiome in Patients With Severe COPD |
Active, not recruiting |
NCT02972476 |
Phase 4 |
Budesonide & formoterol fumarate and Aclidinium bromide;Fluticasone 500 & salmeterol and Aclidinium bromide;Fluticasone 250 & salmeterol and Aclidinium bromide;Aclidinium bromide & formoterol fumarate |
31 |
A Prospective, Open-label, Interventional Phase IV Study to Assess the Safety of EupentaTM Inj. {Fully Liquid Pentavalent Vaccine, Adsorbed Diphtheria-Tetanus-whole-cell Pertussis-Hepatitis B (rDNA [Recombinant-deoxyribonucleic Acid])-Haemophilus Influenzae Type b Conjugate Vaccine} |
Not yet recruiting |
NCT04056728 |
Phase 4 |
|
32 |
A Phase IV, Non-Inferiority, Observer Blind, Randomized Clinical Study Comparing Safety And Immunogenicity Of DTP-HB-Hib Vaccination by Disposable-Syringe Jet Injector To Vaccination By Needle And Syringe In Healthy Infants In India |
Terminated |
NCT02409095 |
Phase 4 |
|
33 |
Assessment of Antibody Responses in UK Infants Given Two Doses of 10 or 13 Valent Pneumococcal Conjugate Vaccine (PCV) in Infancy and PCV13 in the Second Year of Life (Study Code: Pneumococcal in New Combinations (PINC)) |
Withdrawn |
NCT02918708 |
Phase 4 |
|
34 |
A Phase III, Double Blind, Parallel-controlled, Randomised Study to Evaluate the Safety and Immunogenicity of Haemophilus Influenzae Type b Conjugate Vaccine in Healthy Children 2 Months to 5 Years of Age |
Unknown status |
NCT02560272 |
Phase 3 |
|
35 |
A Phase III, Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Protective Efficacy of Three Doses of Oral Rotavirus Vaccine (ORV) 116E, Against Severe Rotavirus Gastroenteritis in Infants |
Unknown status |
NCT01305109 |
Phase 3 |
|
36 |
An Open Label Trial of Azithromycin in Chronic Productive Cough |
Unknown status |
NCT02196493 |
Phase 3 |
Azithromycin |
37 |
A Study of Safety and Immunogenicity of 10-valent and 13-valent Pneumococcal Conjugate Vaccines to Inform Policy Regarding Pneumococcal Vaccination of Papua New Guinean Children |
Unknown status |
NCT01619462 |
Phase 3 |
|
38 |
Randomized Study on Efficacy of Gemifloxacin-based Regimen for Helicobacter Pylori Infection |
Unknown status |
NCT02368470 |
Phase 3 |
Gemifloxacin-based triple therapy;Standard triple therapy |
39 |
Randomized Controlled Trial Comparing Long and Short Duration of Antibiotic Prophylaxis for Patients Undergoing Sinus Lift Surgery |
Unknown status |
NCT02764710 |
Phase 3 |
Amoxicillin-Potassium Clavulanate Combination |
40 |
A Single-blind, Randomized, Controlled, Multinational Study for the Evaluation of Safety of GlaxoSmithKline (GSK) Biologicals' Investigational Vaccination Regimen Compared to Monovalent Haemophilus Influenzae Type b (Hib) Control Vaccine in Healthy Infants at 2, 4, 6, and 12 to 15 Months of Age. |
Completed |
NCT00345579 |
Phase 3 |
|
41 |
Assessment of the Immunogenicity and Safety of Quinvaxem Vaccine (DTwP-HepB-Hib) Against Diphtheria, Pertussis, Tetanus, Hepatitis B and Diseases Caused by H. Influenzae Among Healthy Vietnamese Children |
Completed |
NCT01362517 |
Phase 3 |
|
42 |
A Phase III Open Label, Multi-Center Pediatric Study in China Comparing Booster Doses of Vaxem Hib and Hiberix Vaccines for the Prevention of Haemophilus Influenzae Type b (Hib) Infection |
Completed |
NCT01025544 |
Phase 3 |
|
43 |
Single-blind, Randomized, Controlled, Multinational Study for the Evaluation of Safety of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to Monovalent Hib Control Vaccine in Healthy Infants at 2, 4, 6, and 12 to 15 Months of Age. |
Completed |
NCT00345683 |
Phase 3 |
|
44 |
Impact on Nasopharyngeal Carriage, Acute Otitis Media, Immunogenicity and Safety of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A |
Completed |
NCT00839254 |
Phase 3 |
|
45 |
Evaluation of Effectiveness of GSK Biologicals' Pneumococcal Conjugate Vaccine 1024850A Against Invasive Disease |
Completed |
NCT00861380 |
Phase 3 |
|
46 |
A Phase III, Observer-blind, Randomized, Controlled, Multicenter Study to Investigate Immunogenicity and Safety of Haemophilus Influenzae Type b Vaccine in 2 - 4 Months Old Healthy Infants in China, According to the Recommended Regimen of 3 Intramuscular Doses Given One Month Apart |
Completed |
NCT00808392 |
Phase 3 |
|
47 |
A Phase III Observer Blind Single-Coordinating Center Pediatric Study in China Comparing a Booster Dose of Vaxemâ„¢ Hib to HIBERIX® When Given as Part of a Local Dosing Regimen in Infants |
Completed |
NCT01226953 |
Phase 3 |
|
48 |
A Phase IIIb, Controlled, Open Label, Single-Center, Persistency, Extension Study in Chinese Children After a 2+1 Dose Series of Either CRM197-Conjugate Haemophilus Influenzae Type b Vaccine or Tetanus Toxoid-Conjugate Haemophilus Influenzae Type b Vaccine |
Completed |
NCT02139228 |
Phase 3 |
|
49 |
A Phase III Observer-blind, Randomized, Controlled, Single-coordinating Center Study to Investigate Immunogenicity and Safety of a Monovalent Glycoprotein-conjugated (Diptheria Toxin -CRM197) Hib Vaccine in 13-59 Months Old Healthy Children in China, According to the Recommended Regimen of 1 Dose |
Completed |
NCT01125527 |
Phase 3 |
|
50 |
A Multicentre, Comparative, Two-arm, Parallel-group, Double-blind, Randomized Phase III Study to Assess Immunogenicity and Safety of LBVH0101 (Haemophilus Influenzae Type b Tetanus Toxoid Conjugate Vaccine) Compared With Hiberixâ„¢ Vaccine in Healthy Infants at Two, Four and Six Months of Age |
Completed |
NCT01019772 |
Phase 3 |
|
|